Objective:To investigate the influence of different antiplatelet therapies on the platelet activation and aggregation in patients with acute cerebral infarction. Methods:CD62P was measured by flow cytometry,arachidonic acid-induced platelet maximal aggregation rate(MARAA),adenosine diphosphate-induced platelet maximal aggregation rate(MARADP)were performed by turbidimetry. A total of 97 cerebral infarction patients were randomly divided into different antiplatelet therapy groups(the aspirin group,the clopidogrel group and the aspirin plus clopidogrel group). CD62P,MARAA and MARADP were measured on the 1st day (before treatment)and 10th day after admission. Results:On the first day,comparisons of CD62P,MARAA and MARADP among the three treatment groups were not significant. The levels of CD62P,MARAA and MARADP in each group were significantly decreased from 1 day to 10 day after admission. Comparison of MARADP decrease extent among the three treatment groups was significant,MARADP of the aspirin plus clopidogrel group decreased more distinctly than the clopidogrel group and even more than the aspirin group. Comparisons of CD62P and MARAA decrease extent among three treatment groups was not significant. Conclusion:Three antiplatelet therapies(aspirin,clopidogrel,aspirin plus clopidogrel) all reduced platelet activation and maximum aggregation rate,which indicated that each antiplatelet therapy was effective. Aspirin plus clopidogrel therapy could most significantly reduce platelet aggregation,which indicated that the curative effect was better among three antiplatelet therapys.